Relevant bibliographies by topics / Cyclooxygenase-2 (COX-2) Inhibitors

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Cyclooxygenase-2 (COX-2) Inhibitors'

Author: Grafiati
Published: 5 June 2025
Last updated: 1 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Cyclooxygenase-2 (COX-2) Inhibitors.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Cyclooxygenase-2 (COX-2) Inhibitors"

1

Rubin, Bernard R. "Specific cyclooxygenase-2 (COX-2) inhibitors." Journal of the American Osteopathic Association 99, no. 6 (1999): 322. http://dx.doi.org/10.7556/jaoa.1999.99.6.322.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Reitz, David B., and Peter C. Isakson. "Cyclooxygenase-2 Inhibitors." Current Pharmaceutical Design 1, no. 2 (1995): 211–20. http://dx.doi.org/10.2174/1381612801666220917221427.

Full text
Abstract:
Prostaglandins are synthesized by the enzyme cyclooxygenase (COX), which is the target for nonsteroidal anti-inflammatory drugs (NSAIDs). Recently a second form of COX was discovered (COX-2) that is induced by inflammatory stimuli. The identification of an inducible form of COX led to the hypothesis that COX-2 is responsible for inflammatory prostaglandins, whereas the constitutive COX-I produces physiologically important prostaglandins, e.g., in stomach and kidney. Selective COX- 2 inhibitors have been shown to be anti-inflammatory but do not cause ulcers in the stomach or intestines. It is a
APA, Harvard, Vancouver, ISO, and other styles
3

NAKAMURA, Hideo. "Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors." Folia Pharmacologica Japonica 118, no. 3 (2001): 219–30. http://dx.doi.org/10.1254/fpj.118.219.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Sharma, Rajesh, Jitendra Sainy, and Subhash Chaturvedi. "2-Amino-5-sulfanyl-1,3,4-thiadiazoles: A new series of selective cyclooxygenase-2 inhibitors." Acta Pharmaceutica 58, no. 3 (2008): 317–26. http://dx.doi.org/10.2478/v10007-008-0011-6.

Full text
Abstract:
2-Amino-5-sulfanyl-1,3,4-thiadiazoles: A new series of selective cyclooxygenase-2 inhibitorsA new series of cyclooxygenase-2 inhibitors with 2-amino--5-sulfanyl-1,3,4-thiadiazole as the central scaffold unit has been synthesized. The newly synthesized compounds were characterized by analytical and spectral methods. Compounds were screened for cyclooxygenase inhibitory activity by the colorimetric COX (ovine) inhibitor screening assay, anti-inflammatory activity by the carrageenean induced rat paw oedema test and analgesic activity by the tail flick method. Some compounds exhibited significant
APA, Harvard, Vancouver, ISO, and other styles
5

Milas, Luka. "Cyclooxygenase-2 (COX-2) Enzyme Inhibitors and Radiotherapy." American Journal of Clinical Oncology 26, Supplement 2 (2003): S66—S69. http://dx.doi.org/10.1097/01.coc.0000074160.49879.51.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Talley, John J., Stephen R. Bertenshaw, David L. Brown, et al. "4,5-Diaryloxazole inhibitors of cyclooxygenase-2 (COX-2)." Medicinal Research Reviews 19, no. 3 (1999): 199–208. http://dx.doi.org/10.1002/(sici)1098-1128(199905)19:3<199::aid-med1>3.0.co;2-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Grösch, Sabine, Thorsten Jürgen Maier, Susanne Schiffmann, and Gerd Geisslinger. "Cyclooxygenase-2 (COX-2)–Independent Anticarcinogenic Effects of Selective COX-2 Inhibitors." JNCI: Journal of the National Cancer Institute 98, no. 11 (2006): 736–47. http://dx.doi.org/10.1093/jnci/djj206.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Mengle-Gaw, Laurel J., and Benjamin D. Schwartz. "Cyclooxygenase-2 inhibitors: promise or peril?" Mediators of Inflammation 11, no. 5 (2002): 275–86. http://dx.doi.org/10.1080/09629350290000041.

Full text
Abstract:
The discovery of two isoforms of the cyclooxygenase enzyme, COX-1 and COX-2, and the development of COX-2-specific inhibitors as anti-inflammatories and analgesics have offered great promise that the therapeutic benefits of NSAIDs could be optimized through inhibition of COX-2, while minimizing their adverse side effect profile associated with inhibition of COX-1. While COX-2 specific inhibitors have proven to be efficacious in a variety of inflammatory conditions, exposure of large numbers of patients to these drugs in postmarketing studies have uncovered potential safety concerns that raise
APA, Harvard, Vancouver, ISO, and other styles
9

Ray, Neelanjana, Margaret E. Bisher, and L. W. Enquist. "Cyclooxygenase-1 and -2 Are Required for Production of Infectious Pseudorabies Virus." Journal of Virology 78, no. 23 (2004): 12964–74. http://dx.doi.org/10.1128/jvi.78.23.12964-12974.2004.

Full text
Abstract:
ABSTRACT We have recently shown that cyclooxygenase-2 (COX-2) transcription is markedly induced after herpes simplex virus type 1 and pseudorabies virus (PRV) infections of rat embryonic fibroblast (REF) cells (N. Ray and L. W. Enquist, J. Virol. 78:3489-3501, 2004). For this study, we investigated the role of cyclooxygenase induction in the replication and growth of PRV. We demonstrate here a concordant increase in COX-2 mRNA and protein levels after the infection of REF cells. Inhibitors blocking the activity of cyclooxygenases caused a dramatic reduction in PRV growth. Viral growth could be
APA, Harvard, Vancouver, ISO, and other styles
10

Pavan, Prabhakar Chinchole, Suresh Adhao Vaibhav, Suresh Adhao Vaibhav, Devidas Mehetre Gautam, Ramesh Thenge Raju, and Ramesh Popat Ritesh. "In Silico study of 3-D structural interactions and quantitative structural drug likeness of marketed Cox-2 inhibitors." GSC Biological and Pharmaceutical Sciences 19, no. 1 (2022): 149–53. https://doi.org/10.5281/zenodo.6624284.

Full text
Abstract:
In the field of molecular modeling, docking may be a method which predicts the well-liked orientation of any molecule to a receptor to make a stable complex. Knowledge of the well-liked orientation successively could also be able to predict the strength of association or binding affinity between two molecules using, for instance, scoring functions. Cyclooxygenase-2 (COX-2) inhibitors block cyclooxygenase-2 (COX-2), an enzyme that promotes inflammation. COX-2 enzyme converts to prostaglandin via arachidonic acid, causing pain and inflammatory responses. They are mainly present in places of infl
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Cyclooxygenase-2 (COX-2) Inhibitors"

1

Kim, Janet Heejung. "Cyclooxygenase-2 Expression in Post-Mastectomy Chest Wall Relapse." Yale University, 2006. http://ymtdl.med.yale.edu/theses/available/etd-06282006-104942/.

Full text
Abstract:
The purpose of this study was to assess the prognostic significance and clinical correlations of cyclooxgenase-2 expression (COX) in a cohort of patients treated with radiation (RT) for post-mastectomy chest wall relapse (PMCWR). Between 1975 and 1999, 113 patients were treated for isolated PMCWR. All patients were treated with biopsy and/or excision of the CWR followed by RT. Median follow-up was 10 years. All clinical data including demographics, pathology, staging, receptor status, HER-2/neu status, and adjuvant therapy were entered into a computerized database. Paraffin-embedded CWR specim
APA, Harvard, Vancouver, ISO, and other styles
2

Bühler, Nico Martin. "Selektive COX-2 Inhibitoren und Nierenschädigung bei salzsensitiver Hypertonie /." [S.l.] : [s.n.], 2009. http://opac.nebis.ch/cgi-bin/showAbstract.pl?sys=000297941.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Fürstenberg, Antje. "Einfluß des Cyclooxygenase-2-Inhibitors NS-398 auf Proliferation und Apoptose von Ovarialkarzinomzellinien." Doctoral thesis, Humboldt-Universität zu Berlin, Medizinische Fakultät - Universitätsklinikum Charité, 2005. http://dx.doi.org/10.18452/15175.

Full text
Abstract:
Mehrere Studien haben gezeigt, daß die Cyclooxygenase-2 (COX-2) eine bedeutende Rolle sowohl bei Entstehung als auch Progression maligner Tumoren spielt. COX-2-Inhibitoren werden bereits in klinischen Studien zur Krebstherapie getestet. COX-2 ist die induzierbare Isoform der Cyclooxygenase - dem Schlüsselenzym der Synthese von Prostaglandinen und anderen Eicosanoiden. Im Tier- und Zellkulturmodell konnten COX-Hemmer anti-Tumor-Effekte hervorrufen. Es ist jedoch unklar, ob diese Effekte durch Hemmung des COX-Enzyms oder durch COX-unabhängige Mechanismen vermittelt werden. Wir untersuchten
APA, Harvard, Vancouver, ISO, and other styles
4

Mehar, Ayaz. "Inhibitors of cyclooxygenase-2 (COX-2) and prostate cancer : effects on apoptosis and role in tumour inhibition." Thesis, University of Surrey, 2005. http://epubs.surrey.ac.uk/843556/.

Full text
Abstract:
In comparison to other cancers, advanced prostate cancer is resistant to chemotherapy. There is a need to understand the mechanisms which are responsible for this resistance and find better treatments for this disease or methods to increase the efficacy of current treatments. Cancer cells often evade apoptosis. Cyclooxygenase-2 (COX-2) is an enzyme reported to be elevated in prostate cancer, and has oncogenic properties, including apoptosis attenuation. Because of this, COX-2 inhibition could be beneficial for both prevention and treatment of cancer. This study showed that COX-2 protein was no
APA, Harvard, Vancouver, ISO, and other styles
5

Gu, Baoying. "Selective increase of neuronal cyclooxygenase-2 (COX-2) expression in vulnerable brain regions of rats with experimental Wernicke's encephalopathy : effects of nimesulide." Thesis, McGill University, 2007. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=112627.

Full text
Abstract:
Wernicke's encephalopathy is a neuropsychiatric disorder resulting from thiamine deficiency (TD) and is characterized by neuronal loss, astrocytic proliferation and microglial activation. Cyclooxygenases (COX) are enzymes which catalyze the first step in the synthesis of prostanoids. COX-1 is expressed constitutively and COX-2 is the inducible isoform. Groups of TD rats and pair-fed controls were killed at presymptomatic and symptomatic stages of encephalopathy. Cresyl violet and NeuN staining showed decreased numbers of neuronal cells in vulnerable regions (medial thalamus and inferior collic
APA, Harvard, Vancouver, ISO, and other styles
6

Sawdy, Robert John. "The role of the type-2 isoform of the cyclooxygenase enzyme (COX-2) in human parturition : potential benefits of selective COX-2 inhibitors in the management of preterm labour." Thesis, Imperial College London, 2003. http://hdl.handle.net/10044/1/11444.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Davies, Richard. "Effect of selective COX-2 inhibitors on hepatic progenitor cells and the pathologies of experimental hepatocarcinogenesis." University of Western Australia. School of Medicine and Pharmacology, 2007. http://theses.library.uwa.edu.au/adt-WU2007.0190.

Full text
Abstract:
[Truncated abstract] Hepatocellular carcinoma (HCC) is the major malignancy complicating chronic liver disease. New therapies for the prevention of HCC are required due to the limited success and high tumour recurrence rates of existing treatments. Emerging evidence suggests that HCC arise from the transformation of adult liver progenitor cells (LPCs), which have the capacity to differentiate into hepatocytes and biliary cells during liver regeneration. LPC activation precedes neoplasia in experimental hepatocarcinogenesis. LPCs share antigenic epitopes with HCCs, including α-fetoprotein (AFP)
APA, Harvard, Vancouver, ISO, and other styles
8

Mukherjee, Kamalika. "ROLE OF CYCLOOXYGENASE-2 IN ABDOMINAL AORTIC ANEURYSMS IN MICE." UKnowledge, 2012. http://uknowledge.uky.edu/pharmacy_etds/29.

Full text
Abstract:
Abdominal aortic aneurysm (AAA) is a chronic inflammatory disease with no available pharmacological treatment. AAA formation reduces the structural integrity of the vessel and increases the susceptibility to rupture. The inflammatory response within human aneurysmal tissue is characterized by increased expression of cyclooxygenase-2 (COX-2). Similarly, in a mouse model of the disease induced by chronic Angiotensin II (AngII) infusion, we have shown that COX-2 expression in the abdominal aortic smooth muscle layer increases early in the development of the disease. Furthermore, genetic or pharma
APA, Harvard, Vancouver, ISO, and other styles
9

Valkealahti, M. (Maarit). "The effects of bisphosphonates and COX-2 inhibitors on the bone remodelling unit." Doctoral thesis, University of Oulu, 2008. http://urn.fi/urn:isbn:9789514288548.

Full text
Abstract:
Abstract Bone remodelling occurs in humans throughout life, therefore bone is continuously renewed to better respond to changes in weightbearing circumstances. Bone remodelling is extremely vulnerable during fracture healing and integration of prostheses into the surrounding bone. Bone remodelling is a complex system in which many growth factors, cytokines and enzymes, which are essential for the differentiation of osteoblasts and osteoclasts, are involved. Some widely used drugs can affect this sensitive system of remodellation in unexpected manner. Painkillers such as cyclooxygenase (COX) in
APA, Harvard, Vancouver, ISO, and other styles
10

Laube, Markus. "Synthese von Cyclooxygenase-2-Inhibitoren als Grundlage für die funktionelle Charakterisierung der COX-2-Expression mittels PET." Doctoral thesis, Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2015. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-160091.

Full text
Abstract:
Eine erhöhte COX-2-Expression wird bei Krankheiten wie rheumatoider Arthritis aber auch Parkinson, Alzheimer und Krebs beobachtet. Die nichtinvasive Visualisierung und Quantifizierung der COX 2-Expression in vivo mittels Positronen-Emissions-Tomographie (PET) könnte wertvolle Beiträge zur Diagnose dieser Krankheiten liefern. Zur Nutzung der PET-Technik werden geeignete COX-2-adressierende Radiotracer benötigt, deren Entwicklung auch die Identifizierung neuer, der Radiomarkierung zugänglicher COX-2-Inhibitoren als Leitstrukturen voraussetzt. Ziel dieser Arbeit war die Synthese von selektiven,
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Cyclooxygenase-2 (COX-2) Inhibitors"

1

Masline, Shelagh Ryan. Celebrex: Cox-2 inhibitors--the amazing new pain fighters. Avon Books, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

E, Harris Randall, ed. Inflammation in the pathogenesis of chronic diseases: The COX-2 controversy. Springer, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

R, Vane John, Botting Regina M, William Harvey Research Conference (1997 : Phuket, Thailand), and William Harvey Research Conference (1998 : Boston, Mass.), eds. Clinical significance and potential of selective COX-2 inhibitors: The combined proceedings of the William Harvey Conferences held in Phuket, Thailand, on 18-19 September, 1997 and in Boston, USA, on 23-24 April, 1998, supported by an educational grant from Boehringer Ingelheim. William Harvey Press, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

G, Bazán Nicolás, Botting Jack H, and Vane John R, eds. New targets in inflammation: Inhibitors of COX-2 or adhesion molecules : proceedings of a conference held on April 15-16, 1996, in New Orleans, USA, supported by an educational grant from Boehringer Ingelheim. Kluwer Academic Publishers, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

(Editor), Michel Pairet, and Joanne van Ryn (Editor), eds. COX-2 Inhibitors (Milestones in Drug Therapy). Birkhäuser Basel, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Howardell, Maynard J. Trends in Cox-2 Inhibitor Research. Nova Science Publishers, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Masline, Shelagh R. Celebrex :: Cox-2 Inhibitors--the Amazing New Pain Fighters. Avon, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Howardell, Maynard J. Cox-2 Inhibitor Research. Nova Science Publishers, Incorporated, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

LaValle, James B. The Cox-2 Connection: Natural Breakthrough Treatments for Arthritis, Alzheimer's, and Cancer. Healing Arts Press, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

COX-2 blockade in cancer prevention and therapy. Humana Press, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Cyclooxygenase-2 (COX-2) Inhibitors"

1

Browner, M. F. "The structure of human cyclooxygenase-2 and selective inhibitors." In Selective COX-2 Inhibitors. Springer Netherlands, 1998. http://dx.doi.org/10.1007/978-94-011-4872-6_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Gately, S., and R. Kerbel. "Therapeutic Potential of Selective Cyclooxygenase-2 Inhibitors in the Management of Tumor Angiogenesis." In COX-2. KARGER, 2003. http://dx.doi.org/10.1159/000071373.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hawk, E. T., J. L. Viner, and A. Umar. "Non-Steroidal Anti-Inflammatory and Cyclooxygenase-2-Selective Inhibitors in Clinical Cancer Prevention Trials." In COX-2. KARGER, 2003. http://dx.doi.org/10.1159/000071375.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Maurer, Christoph A., and Katharina M. Kessler. "Effects of cyclooxygenase-2 (COX-2) inhibitors in colorectal cancer." In Cancer and Inflammation. Birkhäuser Basel, 2004. http://dx.doi.org/10.1007/978-3-0348-7861-6_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Blanke, C. D., and J. L. Masferrer. "Chemotherapy with Cyclooxygenase-2 Inhibitors in the Treatment of Malignant Disease: Pre-Clinical Rationale and Preliminary Results of Clinical Trials." In COX-2. KARGER, 2003. http://dx.doi.org/10.1159/000071376.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Christoph, Thomas, and Helmut Buschmann. "Cyclooxygenase Inhibition: From NSAIDS to Selective COX-2 Inhibitors (part 2)." In Analgesics. Wiley-VCH Verlag GmbH & Co. KGaA, 2005. http://dx.doi.org/10.1002/3527605614.ch2b.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Burd, Randy, Hak Choy, and Adam Dicker. "Potential for Inhibitors of Cyclooxygenase-2 to Enhance Tumor Radioresponse." In COX-2 Blockade in Cancer Prevention and Therapy. Humana Press, 2003. https://doi.org/10.1007/978-1-59259-302-6_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Christoph, Thomas, and Helmut Buschmann. "Cyclooxygenase Inhibition: From NSAIDS to Selective COX-2 Inhibitors (part 1)." In Analgesics. Wiley-VCH Verlag GmbH & Co. KGaA, 2005. http://dx.doi.org/10.1002/3527605614.ch2a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Christoph, Thomas, and Helmut Buschmann. "Cyclooxygenase Inhibition: From NSAIDS to Selective COX-2 Inhibitors (part 3)." In Analgesics. Wiley-VCH Verlag GmbH & Co. KGaA, 2005. http://dx.doi.org/10.1002/3527605614.ch2c.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Patrono, C., F. Cipollone, G. Renda, and P. Patrignani. "Cyclooxygenase enzymes in human vascular disease." In Selective COX-2 Inhibitors. Springer Netherlands, 1998. http://dx.doi.org/10.1007/978-94-011-4872-6_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Cyclooxygenase-2 (COX-2) Inhibitors"

1

Damayanti, Sophi, Andhika Bintang Mahardhika, Slamet Ibrahim, Wei Lim Chong, Vannajan Sanghiran Lee, and Daryono Hadi Tjahjono. "O-desmethylquinine as a cyclooxygenase-2 (COX-2) inhibitors using AutoDock Vina." In 3RD INTERNATIONAL CONFERENCE ON FUNDAMENTAL AND APPLIED SCIENCES (ICFAS 2014): Innovative Research in Applied Sciences for a Sustainable Future. AIP Publishing LLC, 2014. http://dx.doi.org/10.1063/1.4898452.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ariza-Rua, Danilo L., Edisson Chavarro-Mesa, Yamil Ballestas-Casallas, Juan Rebollo-Perez, and Wilson Maldonado-Rojas. "Molecular docking studies of 4-nitromonosubstituted chalcone derivatives as cyclooxygenase-2 (COX-2) inhibitors." In 11TH INTERNATIONAL CONFERENCE ON MATHEMATICAL MODELING IN PHYSICAL SCIENCES. AIP Publishing, 2023. http://dx.doi.org/10.1063/5.0163262.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Beteringhe, Adrian, and Flavia Corina Mitroi Symeonidis. "Molecular Docking Technique for selection of some naproxen derivatives as inhibitors of cyclooxygenase 2 (COX-2)." In 2015 7th International Conference on Electronics, Computers and Artificial Intelligence (ECAI). IEEE, 2015. http://dx.doi.org/10.1109/ecai.2015.7301240.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Katanić Stanković, Jelena S., Vanja Todorović, Jelena Đorović Jovanović, et al. "„In vitro“ and „in silico“ assessment of anti-inflammatory activity of cocoa powders." In 2nd International Conference on Chemo and Bioinformatics. Institute for Information Technologies, University of Kragujevac, 2023. http://dx.doi.org/10.46793/iccbi23.156ks.

Full text
Abstract:
Plants are considered the major sources of biologically active compounds, which provide unlimited opportunities for their use either as medical treatments or as novel drug formulations. Cocoa powder is frequently used in nutrition and is known to have many benefits thanks to its wide range of biological activities. The presented study was focused on the evaluation of the anti-inflammatory potential of extracts obtained from cocoa powder. In vitro assays were employed to evaluate the level of inhibition of cyclooxygenases-1 and -2 activities (COX-1 and COX-2) by tested extracts. Molecular docki
APA, Harvard, Vancouver, ISO, and other styles
5

Keta, Otilija, Jelena Bošković, Vladana Petković, et al. "Synthesis and cytotoxic activity of selected dual COX-2 and 5-LOX inhibitors in HeLa and MIA PaCa-2 human cancer cell lines." In 2nd International Conference on Chemo and Bioinformatics. Institute for Information Technologies, University of Kragujevac, 2023. http://dx.doi.org/10.46793/iccbi23.503k.

Full text
Abstract:
Among novel cancer chemotherapy approaches, the use of cyclooxygenases (COXs) and lipoxygenases (LOXs) inhibitors represents a promising mean for cancer treatment showing lesser toxicity comparing to the currently used cytotoxic drugs. This study detailed the synthesis of three novel compounds: 1ME, BHTK-AA, and IBU-Ac, each with the capability to concurrently inhibit both COX-2 and 5-LOX. Subsequently, we assessed their effectiveness in inhibiting the proliferation of HeLa cervical and MIA PaCa-2 pancreatic cancer cells. The IC50 values for both examined cell lines were approximately 40 μM, i
APA, Harvard, Vancouver, ISO, and other styles
6

Branković, Jovica, Vesna Milovanović, and Vladimir P. Petrović. "CYCLOOXYGENASE-2 AS „IN SILICO“ TARGET OF PHENOLIC HYDRAZONE- TYPE DERIVATIVES." In 1st INTERNATIONAL Conference on Chemo and BioInformatics. Institute for Information Technologies, University of Kragujevac, 2021. http://dx.doi.org/10.46793/iccbi21.324b.

Full text
Abstract:
In the present work, a series of phenolic hydrazone analogs were investigated in silico for their potential inhibitory activity toward COX-2. These examinations were based on the capability of hydrazone-based compounds to interact with numerous enzymes, as well as on their versatile biological features and therapeutical applications. COX-2 was selected due to its involvement in the inflammation and carcinogenesis processes. Regarding this, COX-2 represents a valid target for the development of compounds that could block the formation of harmful inflammation mediators.
APA, Harvard, Vancouver, ISO, and other styles
7

Amalia, Atikah, Siti Imroatul Maslikah, and Sri Rahayu Lestari. "Virtual screening flavonoid compounds from red betel (Piper crocatum Ruiz & Pav.) as inhibitor of cyclooxygenase-2 (COX-2)." In PROCEEDINGS OF THE 3RD INTERNATIONAL SEMINAR ON METALLURGY AND MATERIALS (ISMM2019): Exploring New Innovation in Metallurgy and Materials. AIP Publishing, 2020. http://dx.doi.org/10.1063/5.0002567.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Woods, A. I., and M. A. Lazzari. "ASPIRIN FAILURE TO INHIBIT THE RELEASE OF PLASMINOGEN ACTIVATORS-INHIBITORS BY HUMAN PLATELETS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643126.

Full text
Abstract:
Platelet-PA-Inhibitors can be released by thrombin, Col laaen( Col) and others.If they are physiologically important,inhibition of their release might facilitate thrombolysis.Intrinsic PA were tested in euclobulins (eug)of PPP and PPP+Washed platelets(WP) ,with and without aspirinf ASA) .treated with UK,SK and Col(20 atfd l2uo/ml) Results(mm2)were:euaPPP:232+78;+3×106WP/ul:217+71;+10%7ul:188+/5 +2×106MP/ul: 157+69:With UK:eugPPP:283+76;+3×l0517P/ul :234+69;+106 WP/ul :172+55;+2×l(PWP/ul :154+48; With SK:euoPPP:303+99;+3×l05WP/ul 252+65;+1067P/ul:203+68;+2×106UP/ul: 174+85;Wi th Col (20ug/ml) :
APA, Harvard, Vancouver, ISO, and other styles
9

Pinto, Madalena, Carla Fernandes, Andreia Palmeira, et al. "Chiral Derivatives of Xanthones: Investigation of Enantioselectivity as Inhibitors of Cyclooxygenases (COX-1 and COX-2) and Binding Interaction with Human Serum Albumin." In 2nd International Electronic Conference on Medicinal Chemistry. MDPI, 2016. http://dx.doi.org/10.3390/ecmc-2-a023.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Itagaki, Y., A. Suzuki, and K. Higashio. "TISSUE PLASMINOGEN ACTIVATOR (T-PA) PRODUCTION BY HUMAN EMBRYONIC FIBROBLASTS, IMR-90, STIMULATED BY PROTEOSE PEPTONE." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644392.

Full text
Abstract:
In order to study the mechanisms by which t-PA production by IMR-90 cells are induced, lactalbumin hydrolysates, yeast extracts, and peptones were tested for their ability to induce t-PA production by IMR-90 cells. IMR-90 cells were grown to confluency in Dulbecco's modified Eagle's medium(DMEM) supplemented with 10% fetal calf serum at 37°C in 5% CO2 in air. And the cells were maintained in serum free medium containing 1% of each additive. The plasminogen activator activity was determined by fibrin plate method, using urokinase or t-PA from WHO as a standard. It was found that proteose pepton
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Cyclooxygenase-2 (COX-2) Inhibitors"

1

Splitter, Gary, Zeev Trainin, and Yacov Brenner. Lymphocyte Response to Genetically Engineered Bovine Leukemia Virus Proteins in Persistently Lymphocytic Cattle from Israel and the U.S. United States Department of Agriculture, 1995. http://dx.doi.org/10.32747/1995.7570556.bard.

Full text
Abstract:
The goal of this proposal was to identify proteins of BLV recognized by lymphocyte subpopulations and determine the contribution of these proteins to viral pathogenesis. Our hypothesis was that BLV pathogenesis is governed by the T-cell response and that the immune system likely plays an important role in controlling the utcome of infection. Our studies presented in ths final report demonstrate that T cell competency declines with advancing stages of infection. Dramatic differences were observed in lymphocyte proliferation to recombinant proteins encoded by BLV gag (p12, p15, and p24) and env
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Cyclooxygenase-2 (COX-2) Inhibitors' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography